Literature DB >> 2394034

Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase.

R E Spitzer1, A E Stitzel, G C Tsokos.   

Abstract

Anti-idiotypic antibodies to autoantibody against the alternative pathway C3 convertase (C3NeF) were isolated and purified from normal human serum as well as from serum from six patients with membrano-proliferative glomerulonephritis (MPGN). All preparations of anti-id antibody blocked C3NeF deposition on EC3bBb as well as C3NeF stabilization of EC3bBb functional activity. The Ka of these ant-id antibodies for C3NeF was 10(9) liters/mol which is comparable to the Ka of C3NeF for its antigen. In addition, 90% of anti-id antibody isolated from patients with MPGN and 20% isolated from normal individuals resembled Bb and bound to C3b as well as to antibody specific for the Bb portion of Factor B. These anti-id antibodies also resembled C3b and bound to antibody specific for the C3c portion of C3b. Immunization of rabbits with this latter form of anti-id antibody led to the production of functionally active C3NeF. These data indicate that C3NeF anti-idiotypic antibodies exist in two distinct forms, with and without internal imagery of C3bBb, and can occur in both normal individuals and patients with MPGN.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2394034     DOI: 10.1016/0090-1229(90)90019-m

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

Review 2.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Authors:  Y Levy; J George; E Yona; Y Shoenfeld
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

3.  Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; S Watanabe; T Fujita; T Yasugi
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.